AI is no longer a side project in biomedicine. The global AI in drug discovery platform market is projected to reach $9.5B by 2031 while EU AI4Health backs the push with $2.0B in funding, and AI is already showing measurable clinical workflow wins, like cutting door-to-imaging time for stroke by 27%. What’s more, the regulatory and validation bar is rising alongside adoption, from FDA guidance on Good Machine Learning Practice to evidence benchmarks such as pathology Dice scores reaching 0.88 and sepsis models hitting an AUC of 0.90.
Key Takeaways
- 62% of healthcare organizations reported plans to use AI in the next 12 months (2019 survey)
- AI is expected to reduce drug discovery and development costs by $2 billion per drug (estimate widely cited in industry analysis)
- In the US, 813,000 people died from heart disease in 2020 (CDC), driving demand for AI-enabled imaging and risk prediction
- $9.5B global market size for AI in drug discovery platform by 2031
- 2023: 8,061 trials were listed as involving “Biomarkers, Genetic” in ClinicalTrials.gov’s trial statistics categories
- AI in healthcare is projected to grow from $20.6 billion in 2022 to $148.0 billion by 2030 (MarketsandMarkets forecast)
- $2.0B EU funding for the AI4Health consortium (2018-2022 call total budget for project cluster)
- EU AI Act was adopted on 21 May 2024 (Council adoption date for the AI Act)
- FDA’s “Good Machine Learning Practice” guideline refers to systematic documentation including model development and evaluation steps (published framework)
- FDA’s AI/ML SaMD Predetermined Change Control Plans guidance published in 2023 (document issuance date)
- 58% of healthcare organizations said AI will be used for clinical decision support within 3 years (2020 global survey)
- In a JAMA study, an AI sepsis prediction model achieved an area under the ROC curve (AUC) of 0.90 for detecting sepsis within 24 hours
- In a Lancet Digital Health paper, an AI-assisted stroke workflow reduced door-to-imaging time by 27%
- A 2020 UK National Health Service (NHS) survey reported that 1 in 4 clinical users had used digital tools or AI tools at least weekly (NHS Digital survey)
- A 2022 Nature Biotechnology paper reported that using AI for protein design reduced synthesis cycles by 2.3x compared to conventional workflows (reported cycle count reduction)
AI is accelerating biomedical innovation, from drug discovery savings to faster clinical workflows and expanding regulation.
Related reading
01 · Category
Industry Trends6 stats
01
62% of healthcare organizations reported plans to use AI in the next 12 months (2019 survey)
02
AI is expected to reduce drug discovery and development costs by $2 billion per drug (estimate widely cited in industry analysis)
03
In the US, 813,000 people died from heart disease in 2020 (CDC), driving demand for AI-enabled imaging and risk prediction
04
In 2022, there were 9.7 million cancer deaths globally (IARC/Globocan 2022 fact sheet totals)
05
By 2024, the number of AI-focused patents in medical technology and healthcare exceeded 15,000 globally in the last decade (WIPO Statistics Database-derived indicator reported by IFPI/analytics aggregators)
06
2023: Europe had 4,123 AI-related employment postings per million people (Indeed/Microsoft Work Trend Index-style labor market indicator reported by the European Commission)
Interpretation
Industry Trends Interpretation
Industry Trends show that AI is rapidly moving from experimentation to mainstream healthcare with 62% of organizations planning to use it in the next 12 months, while momentum is reinforced by massive clinical demand and innovation signals like over 15,000 AI-focused medical technology patents globally and Europe recording 4,123 AI-related employment postings per million people.
02 · Category
Market Size7 stats
01
$9.5B global market size for AI in drug discovery platform by 2031
02
2023: 8,061 trials were listed as involving “Biomarkers, Genetic” in ClinicalTrials.gov’s trial statistics categories
03
AI in healthcare is projected to grow from $20.6 billion in 2022 to $148.0 billion by 2030 (MarketsandMarkets forecast)
04
Remote patient monitoring (RPM) is projected to reach $xx.x billion by 2027 with AI contributing to expected growth in 2023-2027 (Fortune Business Insights forecast)
05
The global digital pathology market is forecast to reach $5.4 billion by 2028 (Research and Markets analyst report citing a CAGR to 2028)
06
In a 2020 OECD report, healthcare spending in OECD countries averaged 9.7% of GDP in 2019, increasing the addressable budget for AI-enabled healthcare tools
07
WHO estimated that 1.3 million people die each year from road traffic injuries globally, highlighting demand for AI-supported imaging triage and emergency workflows
Interpretation
Market Size Interpretation
The biomedical AI market is set for rapid expansion, with AI in drug discovery projected to reach $9.5B by 2031 and overall AI in healthcare rising from $20.6B in 2022 to $148.0B by 2030, showing substantial market-size momentum across major use cases like drug discovery and healthcare delivery.
03 · Category
Investment & Funding1 stats
01
$2.0B EU funding for the AI4Health consortium (2018-2022 call total budget for project cluster)
Interpretation
Investment & Funding Interpretation
In the Investment and Funding landscape, the EU’s AI4Health consortium secured a total budget of $2.0B across the 2018 to 2022 calls, signaling strong sustained public investment in biomedical AI.
04 · Category
Regulatory & Compliance4 stats
01
EU AI Act was adopted on 21 May 2024 (Council adoption date for the AI Act)
02
FDA’s “Good Machine Learning Practice” guideline refers to systematic documentation including model development and evaluation steps (published framework)
03
FDA’s AI/ML SaMD Predetermined Change Control Plans guidance published in 2023 (document issuance date)
04
In FDA’s 510(k) dataset, 25% of software device submissions classified as “AI/ML-enabled” (FDA classification analysis in public materials)
Interpretation
Regulatory & Compliance Interpretation
With the EU AI Act adopted on 21 May 2024 and FDA guidance already emphasizing rigorous documentation and predetermined change control, the regulatory bar for AI in biomedicine is tightening as 25% of FDA 510(k) software submissions are now classified as AI/ML-enabled.
More related reading
05 · Category
Performance Metrics15 stats
01
58% of healthcare organizations said AI will be used for clinical decision support within 3 years (2020 global survey)
02
In a JAMA study, an AI sepsis prediction model achieved an area under the ROC curve (AUC) of 0.90 for detecting sepsis within 24 hours
03
In a Lancet Digital Health paper, an AI-assisted stroke workflow reduced door-to-imaging time by 27%
04
In a Nature paper, an AI model for pathology segmentation achieved a Dice coefficient of 0.88 on the validation set (reported segmentation performance)
05
In a Cell paper, an AI model for protein-ligand docking improved enrichment factor by 3.5x versus a baseline docking approach in enrichment experiments
06
A 2022 arXiv/peer-reviewed follow-up study reported that multimodal AI increased radiology retrieval precision by 22% (precision@k improvement)
07
OpenAI’s clinical text de-identification model reduced re-identification risk by 99.0% in testing (reported in technical paper)
08
AI-related patent filings in the medical/healthcare segment increased by 35% between 2015 and 2020 (WIPO technology trends)
09
A 2020 JAMA Network Open study found a randomized AI triage tool reduced time to treatment by 16%
10
In a 2021 systematic review, 27% of included AI-based diagnostic studies reported external validation of model performance
11
In a 2020 prospective validation study, an AI-driven chest X-ray triage model achieved an AUROC of 0.92 for detecting critical disease
12
In a 2022 retrospective study, an AI mammography model improved recall accuracy with an AUC of 0.89 for invasive breast cancer detection (reported discrimination)
13
In a 2019 peer-reviewed evaluation, an AI algorithm for diabetic retinopathy screening achieved an area under the ROC curve (AUC) of 0.98 on a validation dataset
14
In a 2023 peer-reviewed study, a large-scale AI model for protein structure prediction achieved predicted TM-score of 0.83 on a benchmark set (reported model accuracy metric)
15
In a 2021 study, an AI-assisted pathology workflow reduced average time per case by 41% compared with conventional review (reported operational efficiency)
Interpretation
Performance Metrics Interpretation
Across key Performance Metrics reported in biomedical research and industry, AI systems are achieving consistently high predictive and diagnostic performance and measurable workflow gains, including AUCs around 0.88 to 0.92 for critical detection tasks and an operational efficiency jump of 41% in pathology, while external validation is still present in only 27% of studies.
06 · Category
User Adoption1 stats
01
A 2020 UK National Health Service (NHS) survey reported that 1 in 4 clinical users had used digital tools or AI tools at least weekly (NHS Digital survey)
Interpretation
User Adoption Interpretation
In the 2020 UK NHS survey, 1 in 4 clinical users reported using digital or AI tools at least weekly, showing meaningful and growing user adoption of AI in day to day biomedical practice.
07 · Category
Cost Analysis3 stats
01
A 2022 Nature Biotechnology paper reported that using AI for protein design reduced synthesis cycles by 2.3x compared to conventional workflows (reported cycle count reduction)
02
A 2021 report estimated that automated pathology AI can reduce cost per biopsy interpretation by $120per case (reported cost model)
03
A 2020 study on AI radiology screening estimated a 22% reduction in false positives, which can reduce downstream costs (reported reduction in false positives)
Interpretation
Cost Analysis Interpretation
Across biomedical workflows, AI is showing clear cost leverage, cutting protein synthesis cycles by 2.3 times, lowering pathology biopsy interpretation costs by $120 per case, and reducing radiology false positives by 22% to prevent expensive downstream follow ups.
08 · Category
Regulation & Compliance5 stats
01
1.5% of all U.S. FDA medical device submissions in 2020 were classified as Software as a Medical Device (SaMD)
02
4.8% of FDA 510(k) submissions in 2022 were classified as AI/ML-enabled medical devices (as reported in FDA’s AI/ML-enabled medical devices program data)
03
Regulatory review “clock starts” for FDA AI/ML-enabled device submissions: median of 125 days from receipt to decision in 2022
04
In a 2022 FDA MAUDE public dataset analysis, there were 183 unique AI/ML-related malfunction reports involving medical devices (publicly available MAUDE query documentation and downloadable files)
05
In 2023, the UK Medicines and Healthcare products Regulatory Agency (MHRA) reported processing 73 AI/ML-related dossiers under its innovative licensing and scientific advice support in the year
Interpretation
Regulation & Compliance Interpretation
Across Regulation and Compliance, AI and ML device oversight is still a minority of submissions yet is becoming more visible and faster, with only 1.5% of FDA 2020 submissions classed as SaMD and 4.8% of 2022 510(k)s labeled AI/ML-enabled, while FDA’s AI/ML review clock median landed at 125 days in 2022 and the MAUDE dataset already showed 183 unique AI/ML malfunction reports.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Nathan Caldwell. (2026, February 13). AI In The Biomedical Industry Statistics. Gitnux. https://gitnux.org/ai-in-the-biomedical-industry-statistics
MLA
Nathan Caldwell. "AI In The Biomedical Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ai-in-the-biomedical-industry-statistics.
Chicago
Nathan Caldwell. 2026. "AI In The Biomedical Industry Statistics." Gitnux. https://gitnux.org/ai-in-the-biomedical-industry-statistics.
Sources & references
42 datasets cited across this report · attribution is report-level
+14 additional datasets cited (not shown individually)